BIO-106

BIO-106 is an antibody-drug conjugate developed by BiOneCure Therapeutics. Its target is TROP2 (the sponsor names Trop-2). The sponsor states: BIO-106 is a novel antibody-drug conjugate targeting the human trophoblast cell surface antigen 2 (Trop-2). ClinicalTrials.gov describes the intervention as: BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05320588, plans to enrol 332 participants with primary completion expected 2024-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.